Nicolas Sergeant
Présentation
Nicolas Sergeant is a full-time research director at Inserm UMRS 1172 Alzheimer & Tauopathies group. He is dedicated to understanding the mechanisms underlying neurodegeneration by identifying biomarkers and therapeutic targets for a family of neurological disorders called Tauopathies. He earned his degree in Biology of Aging in 1994 from the University of Paris Diderot VII/Paris Cité. His Ph.D. focused on characterizing the biochemical signatures of neurological disorders, all of which involve neurofibrillary degeneration characterized by different sets of microtubule-associated Tau proteoform aggregates. He joined Inserm in 2000 as a full-time researcher and began investigating the relationship between the lesion processes of Alzheimer's disease, specifically amyloid and Tau pathology. He developed various methods and tools to understand, identify biological markers, and explore therapeutic options to slow or halt neurodegenerative diseases, including Alzheimer’s Disease and Myotonic Dystrophy. He pioneered novel proteomics techniques to analyze protein aggregates, created biological systems for drug screening and structure-activity relationship studies, and developed polyclonal and monoclonal antibodies as well as transgenic models for studying Tau splicing, seeding, and propagation. His expertise also encompasses medicinal chemistry, therapeutic strategy design, and the development of immunological assays, as well as core skills in biochemistry and molecular biology. He holds 11 patents and has collaborated with pharmaceutical companies such as Alzprotect, Sanofi, Innogenetics, Pfizer, Biogen, and Servier to develop biomarkers and small-molecule drugs targeting Tauopathies and Alzheimer's disease. Notably, Ezeprogind, one of these compounds, recently completed a Phase II clinical trial for Supranuclear Palsy. He also contributed to gene therapy research for myotonic dystrophy, a neuromuscular disorder within the RNAopathy family characterized by Tau mis-splicing, neurofibrillary degeneration, and cognitive impairment, and translation to the clinic is held by Genethon. Nicolas Sergeant has authored over a hundred articles. He serves on numerous committees, including the operational committee of Foundation Plan Alzheimer, the Scientific Committee of L’Association France Alzheimer, the AFM task force on myotonic dystrophy, and the scientific committee of the International DMyotonic dystrophy Congress. He is also an associate editor for Frontiers in Neurology and the Exploration of Neuroprotective Therapy Journal.
Publications
Publications
Concentrations of ProAKAP4 as indicators of sperm quality in commonly used bull semen extenders1st European Symposium on Animal Reproduction, Sep 2023, Nantes (44000), France. pp.198
Communication dans un congrès
hal-04369058
v1
|
|
Decoy gene therapy to reverse RNA toxicity in DM1International Myotonic Dystrophy Consortium Meeting IDMC-13, International Myotonic Dystrophy Consortium, May 2022, Osaka, Japan
Communication dans un congrès
hal-03999213
v1
|
|
|
Sperm-specific protein proAKAP4 as a marker to evaluate sperm quality and fertility of Alpine and Saanen Bucks25. Annual Conference of the Eureopean Society for Domestic Animal Reproduction (ESDAR), Sep 2022, Thessaloniki, Greece. Reproduction in Domestic Animals, 57 (S4), pp.79-79, 2022, Proceedings of the 25th Annual Conference of the Eureopean Society for Domestic Animal Reproduction (ESDAR). ⟨10.1111/rda.14244⟩
Poster de conférence
hal-03839750
v1
|
A decoy-based gene therapy targeting CUGexp-DMPK transcripts in DM16th International Myology Congress, Mar 2019, Bordeaux, France
Poster de conférence
hal-04002587
v1
|
|
A Decoy-Based Gene Therapy to Inhibit RNA Toxicity Associated with Expanded CUGInternational Myotonic Dystrophy Consortium Meeting IDMC-12, Jun 2019, Gothenburg, Sweden
Poster de conférence
hal-04002563
v1
|
|
A decoy-based gene therapy targeting CUGexp-DMPK transcripts in DM1International Myotonic Dystrophy Consortium Meeting IDMC-11, Sep 2017, San Fransisco, United States
Poster de conférence
hal-04002607
v1
|
|
|
|
Frontotemporal lobar degenerations, RNAopathy leading to proteinopathiesAAIC 2017 - Alzheimer's Association International Conference, Jul 2017, Londres, United Kingdom. 13 (7), 2017, ⟨10.1016/j.jalz.2017.06.1982⟩
Poster de conférence
hal-01672304
v1
|
|
|
A β-secretase modulator decreases Tau pathology and preserves short-term memory in a mouse model of neurofibrillary degeneration2021
Pré-publication, Document de travail
hal-03203349
v1
|
Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?Tau Biology, pp.207-216, 2019, ⟨10.1007/978-981-32-9358-8_17⟩
Chapitre d'ouvrage
hal-02541222
v1
|